Table 2. Distribution of alleles and genotypes according to viral suppression status at 6 months of ARVs treatment.
| SNPs | VLS N (%) |
No VLS N (%) |
OR (95% CI) |
P
value |
|
|---|---|---|---|---|---|
| rs3745274 CYP2B6 (N = 153) | |||||
| GG | 30 (33.7) | 25 (39.1) | Ref. | ||
| GT | 49 (55.1) | 30 (46.9) | 1.4 (0.6-2.7) | 0.5 | |
| TT | 10 (11.2) | 9 (14.1) | 0.9 (0.3-2.6) | 1 | |
| GG/GT a | 79 (88.8) | 55 (85.9) | Ref. | ||
| TT | 10 (11.2) | 9 (14.1) | 0.7 (0.3-2) | 0.6 | |
| GG b | 30 (33.7) | 25 (39.1) | Ref. | ||
| GT/TT | 59 (66.3) | 39 60.9) | 1.3 (0.6-2.4) | 0.5 | |
| GG/TT c | 40 (54.1) | 34 (45.9) | Ref. | ||
| GT | 49 (62) | 30 (38) | 1.38 (0.7-2.6) | 0.33 | |
| HWE: p-value | 0.13 | 1 | |||
| rs2279343 CYP2B6 (N = 153) | |||||
| AA | 24 (27) | 31 (48.4) | Ref. | ||
| AG | 52 (58.4) | 26 (40.6) | 2.6 (1.3-5.3) | 0.01 | |
| GG | 13 (14.6) | 7 (11) | 2.4 (0.8-6.9) | 0.12 | |
| AA/AG a | 76 (85.4) | 57 (89.1) | Ref. | ||
| GG | 13 (14.6) | 7 (10.9) | 1.2 (0.5-3.1) | 0.6 | |
| AA b | 24 (27) | 31 (48.4) | Ref. | ||
| AG/GG | 65 (73) | 33 (51.6) | 2.5 (1.3-5) | 0.01 | |
| AA/GG c | 37 (49.3) | 38 (50.7) | Ref. | ||
| AG | 52 (66.7) | 26 (33.3) | 2.05 (1.3-2.9) | 0.03 | |
| HWE: p-value | 0.08 | 0.3 | |||
| rs2740574 CYP3A4 (N = 151) | |||||
| TT | 4 (4.5) | 2 (3.2) | Ref. | ||
| CT | 28 (31.8) | 19 (30.2) | 0.7 (0.1-4.4) | 1 | |
| CC | 56 (63.6) | 42 (66.7) | 0.6 (0.1-3.8) | 1 | |
| TT/TC a | 32 (36.4) | 21 (33.3) | Ref. | ||
| CC | 56 (63.6) | 42 (66.7) | 0.8 (0.4-1.7) | 0.7 | |
| TT b | 4 (4.5) | 2 (3.2) | Ref. | ||
| CT/CC | 84 (95.5) | 61 (96.8) | 0.7 (0.1-3.8) | 1 | |
| TT/CCc | 60 (57.7) | 44 (42.3) | Ref. | ||
| TC | 28 (59.6) | 19 (40.4) | 1.1 (0.5-2.2) | 0.8 | |
| HWE: p-value | 0.8 | 0.8 |
VLS: viral load suppression (HIV-1 RNA copies ml-1less than 50 copies), No VLS (HIV-1 RNA copies ml-1higher than 50 copies),
a
recessive model,
b
dominant model,
c
overdominant model